Base de dados : MEDLINE
Pesquisa : C13.351.500.894.906 [Categoria DeCS]
Referências encontradas : 2362 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 237 ir para página                         

  1 / 2362 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28594779
[Au] Autor:Gaydos CA; Beqaj S; Schwebke JR; Lebed J; Smith B; Davis TE; Fife KH; Nyirjesy P; Spurrell T; Furgerson D; Coleman J; Paradis S; Cooper CK
[Ad] Endereço:Johns Hopkins University, Baltimore, Maryland; Pathology Inc, Torrance, California; the University of Alabama at Birmingham, Birmingham, Alabama; Planned Parenthood Southeastern Pennsylvania, Philadelphia, Pennsylvania; Planned Parenthood Gulf Coast, Houston, Texas; Sidney and Lois Eskenazi Hospital and Indiana University School of Medicine, Indianapolis, Indiana; Drexel University College of Medicine, Philadelphia, Pennsylvania; Planned Parenthood of Southern New England, New Haven, Connecticut; Planned Parenthood Mar Monte, San Jose, California; and BD Diagnostics, Québec, Canada, and Sparks, Maryland.
[Ti] Título:Clinical Validation of a Test for the Diagnosis of Vaginitis.
[So] Source:Obstet Gynecol;130(1):181-189, 2017 Jul.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Vaginitis may be diagnosed as bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis, or coinfection. A new molecular test assays the vaginal microbiome and organisms that cause three common infections. The objective of the trial was to evaluate the clinical accuracy of the investigational test for vaginal swabs collected by patients (self) or clinicians. The primary and secondary outcomes were to compare the investigational test with reference methods for the three most common causes of vaginitis and compare clinician-collected with self-collected swabs. METHODS: We conducted a cross-sectional study in which women with symptoms of vaginitis were recruited at ten clinical centers and consented to the investigation between May and September 2015. The woman collected a vaginal swab, sheathed, and then handed it to the clinician. These swabs were to evaluate how self-collected swabs compared with clinician-collected swabs. The clinician collected an investigational test swab and reference test swabs. From 1,740 symptomatic patients, clinician-collected and self-collected vaginal swabs were evaluated by the molecular test and six tests. The reference methods for bacterial vaginosis were Nugent's score and Amsel's criteria for intermediate Nugent results. The reference methods for Candida infection were isolation of any potential Candida microorganisms from inoculation of two culture media: chromogenic and Sabouraud agar and sequencing. The reference methods for trichomoniasis were wet mount and culture. RESULTS: For clinician-collected swabs, by reference methods, bacterial vaginosis was diagnosed in 56.5%, vaginal candidiasis in 32.8%, trichomoniasis in 8%, and none of the three infections in 24% with a coinfection rate of 20%. The investigational test sensitivity was 90.5% (95% confidence interval [CI] 88.3-92.2%) and specificity was 85.8% (95% CI 83.0-88.3%) for bacterial vaginosis. The investigational test sensitivity was 90.9% (95% CI 88.1-93.1%) and specificity was 94.1% (95% CI 92.6-95.4%) for the Candida group. Sensitivity for Candida glabrata was 75.9% (95% CI 57.9-87.8%) and specificity was 99.7% (95% CI 99.3-99.9%). Investigational test sensitivity was 93.1% (95% CI 87.4-96.3%) and specificity was 99.3% (95% CI 98.7-99.6%) for trichomoniasis. Results from self-collected swabs were similar to clinician-collected swabs. CONCLUSION: A molecular-based test using vaginal swabs collected by clinicians or patients can accurately diagnose most common bacterial, fungal, and protozoan causes of vaginitis. Women and their clinicians seeking accurate diagnosis and appropriate selection of efficacious treatment for symptoms of vaginitis might benefit from this molecular test.
[Mh] Termos MeSH primário: Esfregaço Vaginal/normas
Vaginite/diagnóstico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Candida/isolamento & purificação
Candidíase Vulvovaginal/complicações
Candidíase Vulvovaginal/diagnóstico
Feminino
Seres Humanos
Lactobacillus/isolamento & purificação
Meia-Idade
Valor Preditivo dos Testes
Tricomoníase/complicações
Tricomoníase/diagnóstico
Trichomonas vaginalis/isolamento & purificação
Estados Unidos
Vaginite/microbiologia
Vaginose Bacteriana/complicações
Vaginose Bacteriana/diagnóstico
Adulto Jovem
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE; MULTICENTER STUDY
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170609
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002090


  2 / 2362 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28445268
[Au] Autor:Shen Q; Shu L; Luo H; Hu X; Zhu X
[Ad] Endereço:Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
[Ti] Título:The use of mifepristone in abortion associated with an increased risk of uterine leiomyomas.
[So] Source:Medicine (Baltimore);96(17):e6680, 2017 Apr.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To investigate the association between widespread use of mifepristone in abortions and risk of uterine leiomyomas.We conducted a case-control study of 305 patients with uterine leiomyomas between January 2011 and July 2012; 311 women with ordinary vaginitis were selected as controls during the same period. Data were collected by questionnaires (including past history, life history, menstruation history, reproductive history, abortion history, the use of mifepristone, and uterine leiomyomas risk factors) and calculated by univariate and multivariate conditional logistic regression analyses; odds ratios and its 95% confidence interval were calculated to estimate the risk for uterine leiomyomas.Abortion with mifepristone was one of the risk factors for uterine leiomyomas, and the risk increased with increasing frequency of mifepristone use. Family history of uterine leiomyomas, body mass index, age at menarche, number of full-term delivery, and medical abortion history were also correlated with uterine leiomyomas.The use of mifepristone in abortion will increase the risk to develop uterine leiomyomas.
[Mh] Termos MeSH primário: Aborto Induzido
Leiomioma/epidemiologia
Mifepristona
Neoplasias Uterinas/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Estudos de Casos e Controles
Relação Dose-Resposta a Droga
Escolaridade
Feminino
Seres Humanos
Modelos Logísticos
Menstruação
Meia-Idade
Análise Multivariada
Razão de Chances
Paridade
Estudos Retrospectivos
Fatores de Risco
Inquéritos e Questionários
Vaginite/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
320T6RNW1F (Mifepristone)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170602
[Lr] Data última revisão:
170602
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170427
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000006680


  3 / 2362 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28255605
[Au] Autor:Wang H; Huang Z; Wu Z; Qi X; Lin D
[Ad] Endereço:Department of Obstetrics and Gynecology, Jinshan branch of Shanghai sixth people's hospital, Shanghai Jiaotong University, Shanghai 201500, China.
[Ti] Título:An epidemiological study on vaginitis in 6,150 women of reproductive age in Shanghai.
[So] Source:New Microbiol;40(2):113-118, 2017 Apr.
[Is] ISSN:1121-7138
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:The aim of the present study was to determine the prevalence and risk factors for vaginitis, the proportion of pathogens, and cognition of reproductive age patients on the harmful effects of vaginitis, its risk factors, and treatment. This retrospective study enrolled 6,150 patients admitted to the Shanghai Jinshan Central Hospital from 2011 to 2015 with a chief complaint of abnormal vaginal discharge. A questionnaire was designed to survey the cognition of patients on the harmful effects of vaginitis. Routine gynecological examinations and laboratory tests were performed and the risk factors for contracting vaginitis were analyzed by multifactor logistic regression analysis. The positive pathogen rate was 65.63% (4,036/6,150). Trichomonas infections were diagnosed in 1,416 (35.08%) cases including 761 (18.86%) cases of single trichomonas infections, which was significantly higher than the proportion of any other single pathogen infection (P<0.05). From 2011 to 2015, trichomoniasis and chlamydia infections decreased, but bacteria, candida and mycoplasma infections increased. The questionnaire survey showed a low cognition level on iatrogenic and mother-to-child transmission of vaginal infections as well as the risk of ectopic pregnancy and infertility, and on how to prevent vaginal infections. Logistic multifactor regression analysis revealed that advanced age, a low educational level, farmers, childbearing history and a low income were the risk factors for vaginitis. Women of reproductive age showed a high rate of vaginal infections and more attention should be paid to women with a low education level and income to reduce the incidence of vaginal infections in this population.
[Mh] Termos MeSH primário: Vaginite/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
China/epidemiologia
Feminino
Seres Humanos
Modelos Logísticos
Meia-Idade
Fatores de Risco
Vaginite/microbiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170727
[Lr] Data última revisão:
170727
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170304
[St] Status:MEDLINE


  4 / 2362 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28166965
[Au] Autor:Polasek TCM; Kozicki LE; Pedrosa VB; Weiss RR; Bertol MAF; Camargo CE; Talini R
[Ad] Endereço:Master of Animal Science, School of Life Sciences, Pontifical Catholic University of Paraná, Curitiba, Paraná, Brazil.
[Ti] Título:Impact of a progesterone-releasing intravaginal device and inflammatory reaction on ovarian activity in embryo-recipient anestrus mares.
[So] Source:Theriogenology;90:175-184, 2017 Mar 01.
[Is] ISSN:1879-3231
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This study aimed to correlate the inflammatory reaction (IR) caused by a progesterone-releasing intravaginal device (P4) with ovarian activity and pregnancy rate (PR) in embryo-recipient anestrus mares (to decrease the spring transitional period). 50 animals were assigned to three groups: GP4 (P4 group; n = 16), GP4OH (P4 + oxytetracycline hydrochloride and hydrocortisone sprayed onto the device; n = 14), and GNP4 (no intravaginal P4; n = 20). The administration protocol for GP4 was: Day 0, 750 mg P4 + ovarian examination by ultrasonography (US) + vaginal sample collection; Day 8, US; Day 11, P4 removal + 7.5 mg PGF2α + US + second vaginal sample collection; Days 13 to 16, US; Days 17 to 21, US + 750 IU hCG to mares with follicles 35 mm or more in diameter; Days 19 to 23 US (ovulation check); Days 24 to 28, embryo transfer + intravenous flunixin meglumine; and Days 30, US pregnancy diagnosis. The GP4OH and GNP4 mares received the same administration protocol as GP4, except that no P4 device was administered to the GNP4 group on Day 0. Although neutrophil-mediated IR occurred in the GP4 and GP4OH groups, the IR was significantly reduced in GP4OH as compared with that in GP4 (P < 0.0001). From Day 0 to Day 17, the GP4 and GP4OH mares developed a greater number of follicles per animal than did the GNP4 mares (P < 0.05), and the average diameter of the follicles was larger in the GP4 and GP4OH mares. The ovulation rates in GP4, GP4OH, and GNP4 mares were, respectively, 43.7%, 64.3%, and 30.0%, and ovulation occurred at 6.8, 6.5, and 23 days after P4 removal (P < 0.05). On Day 17, endometrial edema was verified in 50%, 64.2%, and 35.0% of the GP4, GP4OH, and GNP4 mares, and the PRs after embryo transfer were 80%, 100%, and 66.6%, respectively. Although intravaginal devices caused IR in both the device-recipient groups (P = 0.0001), IR and vaginitis had no negative impact on follicle diameter, ovulation rate, period to ovulation after the removal of P4, endometrial edema, or PR. In addition, P4 reactivated the ovarian function and the IR eliminated a large percentage of bacteria (Bacillus spp., Enterobacter spp., Proteus spp., Pseudomonas spp., and Staphylococcus spp.), especially in GP4; the application of oxytetracycline hydrochloride and hydrocortisone on the devices reduced the severity of vaginitis.
[Mh] Termos MeSH primário: Implantes de Medicamento/efeitos adversos
Transferência Embrionária/veterinária
Cavalos
Folículo Ovariano/efeitos dos fármacos
Progesterona/administração & dosagem
Vaginite/veterinária
[Mh] Termos MeSH secundário: Administração Intravaginal
Animais
Escherichia coli/isolamento & purificação
Feminino
Hidrocortisona/administração & dosagem
Folículo Ovariano/fisiologia
Ovulação/efeitos dos fármacos
Oxitetraciclina/administração & dosagem
Gravidez
Taxa de Gravidez
Progesterona/efeitos adversos
Streptococcus/isolamento & purificação
Vaginite/induzido quimicamente
Vaginite/microbiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Implants); 4G7DS2Q64Y (Progesterone); WI4X0X7BPJ (Hydrocortisone); X20I9EN955 (Oxytetracycline)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170208
[St] Status:MEDLINE


  5 / 2362 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28116891
[Au] Autor:Guaraldi C; Costantino M; Costantino D
[Ad] Endereço:Unit of Obstetrics and Gynecology, Valdagno Hospital, Vicenza, Italy - claudia.guaraldi@alice.it.
[Ti] Título:Tyndallized lactic ferments: new possible therapies in treating vaginitis.
[So] Source:Minerva Ginecol;69(1):112-115, 2017 Feb.
[Is] ISSN:1827-1650
[Cp] País de publicação:Italy
[La] Idioma:eng
[Mh] Termos MeSH primário: Lactobacillus
Probióticos/administração & dosagem
Vaginite/terapia
[Mh] Termos MeSH secundário: Feminino
Fermentação
Seres Humanos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170125
[St] Status:MEDLINE
[do] DOI:10.23736/S0026-4784.16.03942-3


  6 / 2362 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:27577677
[Au] Autor:Lethaby A; Ayeleke RO; Roberts H
[Ad] Endereço:Department of Obstetrics and Gynaecology, University of Auckland, Private Bag 92019, Auckland, New Zealand, 1142.
[Ti] Título:Local oestrogen for vaginal atrophy in postmenopausal women.
[So] Source:Cochrane Database Syst Rev;(8):CD001500, 2016 Aug 31.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Vaginal atrophy is a frequent complaint of postmenopausal women; symptoms include vaginal dryness, itching, discomfort and painful intercourse. Systemic treatment for these symptoms in the form of oral hormone replacement therapy is not always necessary. An alternative choice is oestrogenic preparations administered vaginally (in the form of creams, pessaries, tablets and the oestradiol-releasing ring). This is an update of a Chochrane systematic review; the original version was first published in October 2006. OBJECTIVES: The objective of this review was to compare the efficacy and safety of intra-vaginal oestrogenic preparations in relieving the symptoms of vaginal atrophy in postmenopausal women. SEARCH METHODS: We searched the following databases and trials registers to April 2016: Cochrane Gynaecology and Fertility Group Register of trials, The Cochrane Central Register of Controlled Trials (CENTRAL; 2016 issue 4), MEDLINE, Embase, PsycINFO, DARE, the Web of Knowledge, OpenGrey, LILACS, PubMed and reference lists of articles. We also contacted experts and researchers in the field. SELECTION CRITERIA: The inclusion criteria were randomised comparisons of oestrogenic preparations administered intravaginally in postmenopausal women for at least 12 weeks for the treatment of symptoms resulting from vaginal atrophy or vaginitis. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial eligibility and risk of bias and extracted the data. The primary review outcomes were improvement in symptoms (participant-assessed), and the adverse event endometrial thickness. Secondary outcomes were improvement in symptoms (clinician-assessed), other adverse events (breast disorders e.g. breast pain, enlargement or engorgement, total adverse events, excluding breast disorders) and adherence to treatment. We combined data to calculate pooled risk ratios (RRs) (dichotomous outcomes) and mean differences (MDs) (continuous outcomes) and 95% confidence intervals (CIs). Statistical heterogeneity was assessed using the I(2) statistic. We assessed the overall quality of the evidence for the main comparisons using GRADE methods. MAIN RESULTS: We included 30 RCTs (6235 women) comparing different intra-vaginal oestrogenic preparations with each other and with placebo. The evidence was low to moderate quality; limitations were poor reporting of study methods and serious imprecision (effect estimates with wide confidence intervals)1. Oestrogen ring versus other regimensOther regimens included oestrogen cream, oestrogen tablets and placebo. There was no evidence of a difference in improvement in symptoms (participant assessment) either between oestrogen ring and oestrogen cream (odds ratio (OR) 1.33, 95% CI 0.80 to 2.19, two RCTs, n = 341, I(2) = 0%, low-quality evidence) or between oestrogen ring and oestrogen tablets (OR 0.78, 95% CI 0.53 to 1.15, three RCTs, n = 567, I(2) = 0%, low-quality evidence). However, a higher proportion of women reported improvement in symptoms following treatment with oestrogen ring compared with placebo (OR 12.67, 95% CI 3.23 to 49.66, one RCT, n = 67). With respect to endometrial thickness, a higher proportion of women who received oestrogen cream showed evidence of increase in endometrial thickness compared to those who were treated with oestrogen ring (OR 0.36, 95% CI 0.14 to 0.94, two RCTs, n = 273; I(2) = 0%, low-quality evidence). This may have been due to the higher doses of cream used. 2. Oestrogen tablets versus other regimensOther regimens in this comparison included oestrogen cream, and placebo. There was no evidence of a difference in the proportions of women who reported improvement in symptoms between oestrogen tablets and oestrogen cream (OR 1.06, 95% CI 0.55 to 2.01, two RCTs, n = 208, I(2) = 0% low-quality evidence). A higher proportion of women who were treated with oestrogen tablets reported improvement in symptoms compared to those who received placebo using a fixed-effect model (OR 12.47, 95% CI 9.81 to 15.84, two RCTs, n = 1638, I(2) = 83%, low-quality evidence); however, using a random-effect model did not demonstrate any evidence of a difference in the proportions of women who reported improvement between the two treatment groups (OR 5.80, 95% CI 0.88 to 38.29). There was no evidence of a difference in the proportions of women with increase in endometrial thickness between oestrogen tablets and oestrogen cream (OR 0.31, 95% CI 0.06 to 1.60, two RCTs, n = 151, I(2) = 0%, low-quality evidence).3. Oestrogen cream versus other regimensOther regimens identified in this comparison included isoflavone gel and placebo. There was no evidence of a difference in the proportions of women with improvement in symptoms between oestrogen cream and isoflavone gel (OR 2.08, 95% CI 0.08 to 53.76, one RCT, n = 50, low-quality evidence). However, there was evidence of a difference in the proportions of women with improvement in symptoms between oestrogen cream and placebo with more women who received oestrogen cream reporting improvement in symptoms compared to those who were treated with placebo (OR 4.10, 95% CI 1.88 to 8.93, two RCTs, n = 198, I(2) = 50%, low-quality evidence). None of the included studies in this comparison reported data on endometrial thickness. AUTHORS' CONCLUSIONS: There was no evidence of a difference in efficacy between the various intravaginal oestrogenic preparations when compared with each other. However, there was low-quality evidence that intra-vaginal oestrogenic preparations improve the symptoms of vaginal atrophy in postmenopausal women when compared to placebo. There was low-quality evidence that oestrogen cream may be associated with an increase in endometrial thickness compared to oestrogen ring; this may have been due to the higher doses of cream used. However there was no evidence of a difference in the overall body of evidence in adverse events between the various oestrogenic preparations compared with each other or with placebo.
[Mh] Termos MeSH primário: Estrogênios/administração & dosagem
Vagina/patologia
Vaginite/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Intravaginal
Idoso
Atrofia/tratamento farmacológico
Estradiol/administração & dosagem
Estrogênios/efeitos adversos
Feminino
Seres Humanos
Concentração de Íons de Hidrogênio
Isoflavonas/administração & dosagem
Meia-Idade
Pós-Menopausa
Ensaios Clínicos Controlados Aleatórios como Assunto
Comprimidos/administração & dosagem
Vagina/química
Cremes, Espumas e Géis Vaginais/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Estrogens); 0 (Isoflavones); 0 (Tablets); 0 (Vaginal Creams, Foams, and Jellies); 4TI98Z838E (Estradiol)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160901
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD001500.pub3


  7 / 2362 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27514125
[Au] Autor:Grueva E; Kovachev E
[Ti] Título:[CHARACTERISTICS OF VAGINAL ECOSYSTEM IN ENDOCERVICITIS CHLAMYDIALIS].
[So] Source:Akush Ginekol (Sofiia);55(1):3-13, 2016.
[Is] ISSN:0324-0959
[Cp] País de publicação:Bulgaria
[La] Idioma:bul
[Ab] Resumo:The study aims: 1. To analyze and study the specifics of microbiocenoses of exocervix at endocervicitis chlamydialis, to differentiate the spectrum of stimuli, and establish the leading role of Chl. trachomatis in the genesis of this process. 2. To determine the leading role of the method of direct (bed-side) microscopy for early and rapid diagnosis of cervicitis and conducting etiotropic therapy. We determined the incidence of endocervicitis chlamydialis, with cause Chl. trachomatis-45.1%, (319 DIF (+) patients out of 708 surveyed), p <0.05, in the Rousse region. Studies indicator presence or absence of vaginal infection, Trichomonas vaginalis, Gardnerella, Candida, Staphiloocus aureus, E. coli, Proteus, Streptoccocus agalactae, the differences between the two samples in terms of the variable was not statistically significant. In our study, in patients with endocervicitis, the incidence of Trichom. vaginalis is 7.0%, Gardnerella-24.4%, Candida-21.4%, Streptococcus agalactae-7.1%, Staphylococcus aureus-6.3%, E. coli-0.4%, Proteus-0.2%. The frequency of Trichomonas vaginalis, npu nauueHmku c endocervicitis chlamydialis e 3.2%, Gardnerella-10.8%, Candida alb. -9.2%, Candida tropicans-0.2% Streptoccocus agalactae-3.3%, Staphyllococus aureus-2.4%, E.coli-0.0%, Proteus-0.0%.The majority of patients with endocervicitis chlamydialis, no other co-infection unless Chl. trachomatis.
[Mh] Termos MeSH primário: Colo do Útero/microbiologia
Infecções por Chlamydia/epidemiologia
Chlamydia trachomatis/isolamento & purificação
Cervicite Uterina/epidemiologia
Cervicite Uterina/microbiologia
Vagina/microbiologia
[Mh] Termos MeSH secundário: Bulgária/epidemiologia
Infecções por Chlamydia/microbiologia
Coinfecção/epidemiologia
Coinfecção/microbiologia
Feminino
Seres Humanos
Vaginite/epidemiologia
Vaginite/microbiologia
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Mês de entrada:1609
[Cu] Atualização por classe:160812
[Lr] Data última revisão:
160812
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160813
[St] Status:MEDLINE


  8 / 2362 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
PubMed Central Texto completo
Texto completo
[PMID]:27502928
[Au] Autor:Dukers-Muijrers NH; Wolffs PF; Eppings L; Götz HM; Bruisten SM; Schim van der Loeff MF; Janssen K; Lucchesi M; Heijman T; van Benthem BH; van Bergen JE; Morre SA; Herbergs J; Kok G; Steenbakkers M; Hogewoning AA; de Vries HJ; Hoebe CJ
[Ad] Endereço:Department of Sexual Health, Infectious Diseases and Environmental Health, South Limburg Public Health Service (GGD South Limburg), Geleen, The Netherlands. nicole.dukers@ggdzl.nl.
[Ti] Título:Design of the FemCure study: prospective multicentre study on the transmission of genital and extra-genital Chlamydia trachomatis infections in women receiving routine care.
[So] Source:BMC Infect Dis;16:381, 2016 Aug 08.
[Is] ISSN:1471-2334
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In women, anorectal infections with Chlamydia trachomatis (CT) are about as common as genital CT, yet the anorectal site remains largely untested in routine care. Anorectal CT frequently co-occurs with genital CT and may thus often be treated co-incidentally. Nevertheless, post-treatment detection of CT at both anatomic sites has been demonstrated. It is unknown whether anorectal CT may play a role in post-treatment transmission. This study, called FemCure, in women who receive routine treatment (either azithromycin or doxycycline) aims to understand the post-treatment transmission of anorectal CT infections, i.e., from their male sexual partner(s) and from and to the genital region of the same woman. The secondary objective is to evaluate other reasons for CT detection by nucleic acid amplification techniques (NAAT) such as treatment failure, in order to inform guidelines to optimize CT control. METHODS: A multicentre prospective cohort study (FemCure) is set up in which genital and/or anorectal CT positive women (n = 400) will be recruited at three large Dutch STI clinics located in South Limburg, Amsterdam and Rotterdam. The women self-collect anorectal and vaginal swabs before treatment, and at the end of weeks 1, 2, 4, 6, 8, 10, and 12. Samples are tested for presence of CT-DNA (by NAAT), load (by quantitative polymerase chain reaction -PCR), viability (by culture and viability PCR) and CT type (by multilocus sequence typing). Sexual exposure is assessed by online self-administered questionnaires and by testing samples for Y chromosomal DNA. Using logistic regression models, the impact of two key factors (i.e., sexual exposure and alternate anatomic site of infection) on detection of anorectal and genital CT will be assessed. DISCUSSION: The FemCure study will provide insight in the role of anorectal chlamydia infection in maintaining the CT burden in the context of treatment, and it will provide practical recommendations to reduce avoidable transmission. Implications will improve care strategies that take account of anorectal CT. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02694497 .
[Mh] Termos MeSH primário: Infecções por Chlamydia/transmissão
Doenças Retais
Parceiros Sexuais
Vaginite
[Mh] Termos MeSH secundário: Adulto
Antibacterianos/uso terapêutico
Azitromicina/uso terapêutico
Infecções por Chlamydia/diagnóstico
Infecções por Chlamydia/tratamento farmacológico
Chlamydia trachomatis/genética
Estudos de Coortes
DNA Bacteriano/análise
Doxiciclina/uso terapêutico
Feminino
Seres Humanos
Masculino
Países Baixos
Técnicas de Amplificação de Ácido Nucleico
Reação em Cadeia da Polimerase
Estudos Prospectivos
Comportamento Sexual
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (DNA, Bacterial); 83905-01-5 (Azithromycin); N12000U13O (Doxycycline)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170606
[Lr] Data última revisão:
170606
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160810
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1186/s12879-016-1721-x


  9 / 2362 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27442450
[Au] Autor:Gonzalez Moreno C; Fontana C; Cocconcelli PS; Callegari ML; Otero MC
[Ad] Endereço:Facultad de Agronomía y Zootecnia, Universidad Nacional de Tucumán, CONICET, El Manantial, Argentina.
[Ti] Título:Vaginal microbial communities from synchronized heifers and cows with reproductive disorders.
[So] Source:J Appl Microbiol;121(5):1232-1241, 2016 Nov.
[Is] ISSN:1365-2672
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIM: To evaluate changes in the resident microbial population in the cranial vaginal mucosa induced by a progesterone-releasing intravaginal device (PRID) compared to the vaginal microbiota of cows with reproductive disorders. METHODS AND RESULTS: Vaginal discharge was evaluated by clinical examination and a Vaginitis Diagnosis Score was performed by exfoliative cytology. All samples classified as positive and some classified as negative by clinical evaluation were later diagnosed as positive for vaginitis by cytological analysis. Bacterial diversity profiles were performed by PCR-DGGE and clustered according to the reproductive health status of the specimens, revealing a correspondence between the structures of the communities in the vagina and the clinical profile. Representative bands from each group were sequenced and identified as Ruminococcus sp., Dialister sp., Escherichia sp./Shigella sp., Virgibacillus sp., Campylobacter sp., Helcoccoccus sp., Staphylococcus sp., Bacillus sp., Actinopolymorpha sp., Exiguobacterium sp., Haemophilus sp./Histophilus sp., Aeribacillus sp., Porphyromonas sp., Lactobacillus sp. and Clostridium sp. CONCLUSION: Our results contribute to the knowledge of the vaginal microbiome in synchronized heifers showing positive or negative clinical vaginitis. SIGNIFICANCE AND IMPACT OF THE STUDY: This study contributes to the understanding of a dynamic vaginal colonization by bacterial consortiums during the synchronization with a widely used PRID protocol. Also, the results reveal the presence of well-known metritis-related pathogens as well as emerging uterine opportunistic pathogens. The provided information will allow to carry out further studies to elucidate functional roles of these native micro-organisms in the bovine reproductive tract.
[Mh] Termos MeSH primário: Bactérias/isolamento & purificação
Doenças dos Bovinos/microbiologia
Sincronização do Estro
Vagina/microbiologia
Vaginite/veterinária
[Mh] Termos MeSH secundário: Animais
Bovinos
Feminino
Microbiota
Progesterona/administração & dosagem
Vaginite/microbiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
4G7DS2Q64Y (Progesterone)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160722
[St] Status:MEDLINE
[do] DOI:10.1111/jam.13239


  10 / 2362 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27435791
[Au] Autor:Liang Q; Li N; Song S; Zhang A; Li N; Duan Y
[Ad] Endereço:Department of Obstetrics and Gynecology, Tianjin Third Central Hospital, Tianjin, China. liangqian120tj@sina.com.
[Ti] Título:High-dose nifuratel for simple and mixed aerobic vaginitis: A single-center prospective open-label cohort study.
[So] Source:J Obstet Gynaecol Res;42(10):1354-1360, 2016 Oct.
[Is] ISSN:1447-0756
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:AIM: The efficacy and safety of two nifuratel dosages for the treatment of aerobic vaginitis (AV) were compared. METHODS: This was a prospective open-label cohort study of patients diagnosed and treated at the Tianjin Third Central Hospital between January 2012 and December 2013. The co-presence of bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), or/and trichomonal vaginitis (TV; mixed AV) was determined. Patients were randomized to nifuratel-500 (500 mg nifuratel, intravaginal, 10 days) or nifuratel-250 (250 mg nifuratel, intravaginal, 10 days), and followed-up for three to seven days after treatment completion. Primary and secondary outcomes were recovery rate and adverse events, respectively. RESULTS: The study included 142 patients with AV. Age was not significantly different between the groups (n = 71 each), and disease distribution was identical: 29 (40.85%) simple AV and 42 (59.15%) mixed AV (AV + BV, 42.86 %; AV + VVC, 30.95%; AV + TV, 26.19%). In patients with simple AV, the recovery rate did not differ significantly between the nifuratel-500 (26/29, 89.66%) and nifuratel-250 (22/29, 75.86%) groups. In patients with mixed AV, recovery rates were significantly higher in the nifuratel-500 than in the nifuratel-250 group (AV + BV, 88.89% vs 50.00 %; AV + VVC, 76.92 % vs 30.77 %; AV + TV, 90.91 % vs 36.36%; all P < 0.05). Only one patient (nifuratel-500) reported an adverse event (mild anaphylactic reaction). CONCLUSION: Nifuratel 500 mg showed good clinical efficacy for the treatment of AV, particularly mixed AV, and is superior to the 250 mg dosage in the treatment of mixed AV.
[Mh] Termos MeSH primário: Antifúngicos/administração & dosagem
Nifuratel/administração & dosagem
Vaginite/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Antifúngicos/efeitos adversos
Candidíase Vulvovaginal/tratamento farmacológico
Feminino
Seres Humanos
Meia-Idade
Nifuratel/efeitos adversos
Estudos Prospectivos
Resultado do Tratamento
Vaginite por Trichomonas/tratamento farmacológico
Vaginose Bacteriana/tratamento farmacológico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); U60U6P08SP (Nifuratel)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170413
[Lr] Data última revisão:
170413
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160721
[St] Status:MEDLINE
[do] DOI:10.1111/jog.13052



página 1 de 237 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde